oncnursingnews19h
APPs Offer a ‘Unique Lens’ to Myeloma Care
A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers ...
oncnursingnews1d
Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...
oncnursingnews1d
Dorothy N. Pierce
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
oncnursingnews1d
Neil Shah, MD, PhD
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
oncnursingnews1d
Angee Kilmer, BSN, RN-BC
10-Year Data Support Pembrolizumab as Standard for Advanced Melanoma ...
oncnursingnews2d
Amy Sebastian-Deutsch, RN, DNP, CNS, APN, AOCNS
Tools to Monitor for ICANS During Lymphoma Treatment With Bispecific Antibodies, CAR T-Cell Therapy ...
oncnursingnews2d
FDA Approves Isatuximab Plus VRd for Newly Diagnosed Myeloma
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
oncnursingnews3d
NKT2152 Shows Promising Efficacy in Advanced Clear Cell Kidney Cancer
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
oncnursingnews3d
The Evolving Second-Line Treatment Landscape in HR+, HER2- Metastatic Breast Cancer
home / case-based-digest / the-evolving-second-line-treatment-landscape-in-hr-her2-metastatic-breast-cancer During a Community Case Forum series, breast cancer experts discussed the importance of ...
oncnursingnews3d
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...